All In Biotech

Drug Trial Radar · NCT07560618

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

A Phase 4, Open Label Study to Assess Descriptive Classification of Pruritus Over Time With Roflumilast 0.15% Cream in Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Sponsor type
Industry
Collaborators
Arcutis Biotherapeutics, Inc.
First posted
May 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.

Conditions

  • ITCH
  • Atopic Dermatitis

Interventions

  • Roflumilast Cream 0.15%Drug

    topically applied to the affected areas once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of descriptors (besides itch) used to describe skin sensations associated with ADTime frame: From enrollment to end of treatment at 4 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Integrative Skin Science and Research

    Sacramento, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.